Cargando…
Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report
BACKGROUND: Primary advanced, unresectable ovarian cancer (OC) is treated with palliative systemic chemotherapy. Intraperitoneal chemotherapy may be an alternative local maintenance therapy. CASE PRESENTATION: A 75 year old woman with laparoscopically and histologically confirmed unresectable OC was...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216537/ https://www.ncbi.nlm.nih.gov/pubmed/28061769 http://dx.doi.org/10.1186/s12885-016-3004-8 |
_version_ | 1782491931234795520 |
---|---|
author | Tempfer, Clemens B. Hartmann, Franziska Hilal, Ziad Rezniczek, Günther A. |
author_facet | Tempfer, Clemens B. Hartmann, Franziska Hilal, Ziad Rezniczek, Günther A. |
author_sort | Tempfer, Clemens B. |
collection | PubMed |
description | BACKGROUND: Primary advanced, unresectable ovarian cancer (OC) is treated with palliative systemic chemotherapy. Intraperitoneal chemotherapy may be an alternative local maintenance therapy. CASE PRESENTATION: A 75 year old woman with laparoscopically and histologically confirmed unresectable OC was treated with 13 cycles of intraperitoneal cisplatin 7.5 mg/m(2) and doxorubicin 1.5 mg/m(2) over 2 years using laparoscopic pressurized intraperitoneal aerosol chemotherapy (PIPAC). Objective tumor response (tumor regression on histology, stable disease on repeated video-laparoscopy and peritoneal carcinomatosis index) was noted. No Common Terminology Criteria for Adverse Events (CTCAE) > grade 3 were observed. EORTC QLQ-C30 quality of life measurements were stable throughout the therapy. CONCLUSIONS: Repeated intraperitoneal chemotherapy with cisplatin and doxorubicin applied as PIPAC may be an effective maintenance treatment in women with primary advanced, unresectable OC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-3004-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5216537 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-52165372017-01-09 Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report Tempfer, Clemens B. Hartmann, Franziska Hilal, Ziad Rezniczek, Günther A. BMC Cancer Case Report BACKGROUND: Primary advanced, unresectable ovarian cancer (OC) is treated with palliative systemic chemotherapy. Intraperitoneal chemotherapy may be an alternative local maintenance therapy. CASE PRESENTATION: A 75 year old woman with laparoscopically and histologically confirmed unresectable OC was treated with 13 cycles of intraperitoneal cisplatin 7.5 mg/m(2) and doxorubicin 1.5 mg/m(2) over 2 years using laparoscopic pressurized intraperitoneal aerosol chemotherapy (PIPAC). Objective tumor response (tumor regression on histology, stable disease on repeated video-laparoscopy and peritoneal carcinomatosis index) was noted. No Common Terminology Criteria for Adverse Events (CTCAE) > grade 3 were observed. EORTC QLQ-C30 quality of life measurements were stable throughout the therapy. CONCLUSIONS: Repeated intraperitoneal chemotherapy with cisplatin and doxorubicin applied as PIPAC may be an effective maintenance treatment in women with primary advanced, unresectable OC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-3004-8) contains supplementary material, which is available to authorized users. BioMed Central 2017-01-06 /pmc/articles/PMC5216537/ /pubmed/28061769 http://dx.doi.org/10.1186/s12885-016-3004-8 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Case Report Tempfer, Clemens B. Hartmann, Franziska Hilal, Ziad Rezniczek, Günther A. Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report |
title | Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report |
title_full | Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report |
title_fullStr | Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report |
title_full_unstemmed | Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report |
title_short | Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report |
title_sort | intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216537/ https://www.ncbi.nlm.nih.gov/pubmed/28061769 http://dx.doi.org/10.1186/s12885-016-3004-8 |
work_keys_str_mv | AT tempferclemensb intraperitonealcisplatinanddoxorubicinasmaintenancechemotherapyforunresectableovariancanceracasereport AT hartmannfranziska intraperitonealcisplatinanddoxorubicinasmaintenancechemotherapyforunresectableovariancanceracasereport AT hilalziad intraperitonealcisplatinanddoxorubicinasmaintenancechemotherapyforunresectableovariancanceracasereport AT rezniczekgunthera intraperitonealcisplatinanddoxorubicinasmaintenancechemotherapyforunresectableovariancanceracasereport |